Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs), including polycythaemia vera (PV), primary myelofibrosis (PMF) and essential thrombocythaemia (ET), are clonal haematopoietic stem cell disorders characterised by proliferation of one or more myeloid cell lineages. They are closely associated with the JAK2V617F mutation, whose detection is used as a clonal marker in the differential diagnosis of MPN. Despite recent improvements in the molecular diagnosis and therapeutic regimen of these chronic disorders, haematological evolution to blast phase remains a major cause of long-term mortality. The mechanism of MPN transformation is still a matter of some controversy because of insufficient insights into the underlying molecular pathogenesis. The purpose of this article is to summarise the increasing data concerning the mechanism of leukaemic evolution of patients diagnosed with chronic MPN. Chromosomal abnormalities and genes that have been shown to play a potential causative role in chronic-phase acceleration are discussed, as are aberrations that may serve as prognostic markers in the blast phase of MPN.
(PMF) and essential thrombocythaemia (ET) are defined as clonal haematopoietic stem cell disorders. They are characterised by increased proliferation of terminally differentiated myeloid cells.
In recent years, much progress has been made in understanding the molecular origin of these chronic entities. The tyrosine kinase JAK2 and thrombopoietin receptor (MPL) were directly linked to the pathogenesis of MPN with the identification of somatic mutations including JAK2V617F, or rare variants, as well as MPL515. 1, 2 These different mutant alleles all result in a gain of function due to the constitutive activation of tyrosine kinase-dependent cellular signalling pathways. [2] [3] [4] Recently discovered deletions or mutations involving TET2, ASXL1 and IDH1/2 shed more light on possible mechanisms of excessive proliferation in chronic MPN. [5] [6] [7] Among the classic MPNs, PV and ET are relatively indolent disorders, resulting in a modest reduction of lifespan compared with a control population; however, most patients ultimately suffer from one or more severe and potentially fatal complications directly attributable to the disease. By comparison, in most cases PMF has a more severe course and survival is significantly affected. [8] [9] [10] [11] [12] Nonetheless, MPN patients are at a significantly increased risk of transformation to acute myelogenous leukaemia (AML), which is generally associated with a dismal prognosis. The incidence of chronic-phase MPN is two to five cases per 100,000 population per year, 12 whereas leukaemic evolution occurs in 2-5% of these patients with either PV or ET 8, 9 and roughly 20% of cases with PMF. 10, 11 Patients with de novo and secondary AML have a similar spectrum of structural abnormalities, including specific chromosomal sites. The occurrence of cytogenetic changes associated with unfavourable risk such as -7/7q-or complex karyotype is higher in secondary AML.
These changes are most probably induced by the type of therapy given during the chronic phase of MPN. 11, [13] [14] [15] Apart from the chromosomal alterations, cumulative insights have been made into the causative genes that underlie the leukaemic transformation of chronic MPNs.
Recent findings have suggested that transition from heterozygosity to homozygosity for JAK2V617F is associated with an increased hyperproliferative disease and may be important for disease progression, at least from PV to secondary myelofibrosis. 16 Moreover, one longitudinal prospective study suggested that the presence of a JAK2V617F haematopoietic clone was significantly associated with leukaemic transformation in PMF. 17 The role of JAK2V617F in clonal evolution is of particular interest as the examination of its kinetics could potentially allow the prediction of disease acceleration. It could also determine whether treatment with novel JAK2 inhibitors during the chronic phase of MPN may be effective in reducing the incidence of transformation. However, our group at the Cedars-Sinai Medical 18 Taken together, the initial aberrant clone of MPN cells may be JAK2V617F(-) with a higher propensity to undergo clonal evolution, whereas this evolution particularly favours the clone acquiring the JAK2V617F during the chronic phase of MPN. Therefore, the presence of this mutation does not appear to be a prerequisite for the leukaemic transition of MPN, suggesting that additional genetic events are required for full transformation.
One of the molecular mechanisms associated with leukaemic evolution was identified almost two decades ago in a relatively small cohort of MPN patients. 22, 23 Aberrations of the tumour suppressor gene TP53 were associated with prior exposure of these patients to genotoxic agents and leukaemic evolution to MPN blast phase. These individuals had mainly been treated with alkylating agents, including chlorambucil and busulfan, as well as radio-therapeutic regimens (e.g. 32 P). Both therapies are known to cause DNA damage together with a significant rate of TP53 aberrations. 24 It was also noted in patients who underwent leukaemic evolution that either loss of heterozygosity (LOH) at 17p or mutation of TP53 was related to prior exposure to hydroxyurea, a non-alkylating agent. 25, 26 However, large prospective studies of MPN patients concluded that the leukaemogenic potential of this cytoreductive compound by itself is low, whereas the risk increases when hydroxyurea is combined with other chemotherapeutic drugs known to damage DNA. 7, 27, 28 Nevertheless, individuals with MPN who progress to AML may have an aberrant TP53 gene in the absence of exposure to a known mutagen. This is consistent with TP53 alterations being associated with the clonal evolution of many other types of cancers.
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Missense mutations involving the dominantly acting RAS gene family and their signal transduction pathway occur frequently in de novo AML. 30 They also occur in chronic myelomonocytic leukaemia (CMML) and juvenile myelomonocytic leukaemia (JMML), 31 found a critical breakpoint region involving a locus at centromeric band 7q22, whereas the telomeric breakpoint varies from q32 to q36. [39] [40] [41] Interestingly, the minimal deleted region in our SNP-array study was located at 7q22.1, encompassing only two target genes: SH2B2 and CUTL1. SH2B2 regulates and enhances JAK2-mediated cellular responses, 42 and the CUTL1 gene encodes for a CUT family member of the homeodomain proteins that can repress the expression of developmentally regulated myeloid genes. 43 Moreover, genome-wide inspection for minimal regions of duplications/amplifications revealed several interesting genes including PIN1, ICAM1 and CDC37 on 19p as well as ERG on 21q. Whereas the latter three targets have been shown to possess potential pro-growth activity in de novo AML and/or myelodysplastic syndrome, [44] [45] [46] PIN1 is known to be overexpressed in a variety of cancers. It may act as an oncogene via promotion of cell-cycle progression and proliferation. 47 However, whether such lesions impart disease-promoting activity or reflect genetic instability during clonal progression in MPN is currently not delineated.
The identification of novel genetic lesions in MPN will probably not only provide new specific diagnostic, prognostic and therapeutic tools, but also increase understanding of the pathogenesis of the disease and its potential acceleration to AML. Recently, TET2, a member of the ten-eleven-translocation (TET) family of genes, has been found to be mutated in various haematopoietic disorders. 49 While mutant TET2 may co-operate with other mutated genes to induce AML, the potential value of the mutation as a prognostic tool appears to be low, since no correlation has been found between the presence of mutant TET2 and survival or leukaemic transformation. 48 The ASXL1 gene is mutated in approximately 20% of chronic-or blast-phase MPN cases. Analysis of serial samples from patients with MPN that evolved into AML demonstrated that these mutations were always present during the chronic phase of the Haematological Malignancies 
